Hims & Hers Health (NYSE:HIMS) Stock Price Down 6.3% After Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS) was down 6.3% during trading on Tuesday after Citigroup lowered their price target on the stock from $16.50 to $13.25. Citigroup currently has a sell rating on the stock. Hims & Hers Health traded as low as $13.74 and last traded at $14.5370. Approximately 17,816,646 shares changed hands during trading, a decline of 34% from the average daily volume of 26,829,002 shares. The stock had previously closed at $15.51.

Other equities analysts have also issued reports about the stock. BTIG Research lowered shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday. UBS Group set a $32.00 price objective on Hims & Hers Health in a research note on Tuesday, November 4th. Morgan Stanley set a $21.00 target price on Hims & Hers Health in a research report on Tuesday. Deutsche Bank Aktiengesellschaft set a $31.00 price target on Hims & Hers Health and gave the stock a “hold” rating in a report on Tuesday, February 10th. Finally, Truist Financial restated a “hold” rating and issued a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus price target of $32.27.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,090 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80. Following the sale, the chief financial officer directly owned 94,333 shares of the company’s stock, valued at $3,369,574.76. The trade was a 19.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Irene Becklund sold 8,411 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the sale, the insider owned 2,126 shares in the company, valued at approximately $78,045.46. This trade represents a 79.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 82,963 shares of company stock valued at $2,944,621 in the last quarter. 17.71% of the stock is currently owned by insiders.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Beat on EPS and subscriber growth — HIMS reported Q4 revenue up ~28% YoY and an EPS beat while saying subscribers have crossed 2.5 million, showing demand resilience. Hims & Hers Health Reports Mixed Q4 Earnings, Subscribers Cross 2.5 Million
• Positive Sentiment: Acquisition and 2026 revenue guidance provide upside potential — Management projects 2026 revenue of $2.7–$2.9B (above some estimates) and highlighted the Eucalyptus acquisition as an incremental revenue driver. Hims & Hers forecasts 2026 revenue above estimates
• Positive Sentiment: Bullish analyst/features note long‑term growth path — Bullish writeups highlight multi‑year international expansion, Eucalyptus’ contribution and a path to much larger revenue/EBITDA over time. Hims & Hers Health: Don’t Get Lost In The Weeds
• Neutral Sentiment: Unusual options activity — Heavy call buying was reported, which can indicate speculative bullish interest but is not definitive on fundamentals.
• Negative Sentiment: Soft near‑term guidance and margin pressure — Q1 revenue guidance came in below street estimates and margins showed contraction, prompting investor concern about short‑term growth and profitability. Hims & Hers Stock Slips Despite Q4 Earnings Beat, Margins Contract
• Negative Sentiment: Regulatory and SEC scrutiny — The company disclosed an SEC probe and management addressed scrutiny over compounding of GLP‑1 products, raising legal and operational risk for its core weight‑loss business. Hims & Hers Health discloses SEC investigation over copycat GLP-1s; stock falls
• Negative Sentiment: Analyst downgrades and price‑target cuts — Several firms trimmed forecasts and ratings (Citigroup cut its target to $13.25 with a sell), increasing near‑term sell pressure. Analyst price target and rating actions

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in the stock. Quent Capital LLC bought a new stake in Hims & Hers Health during the 3rd quarter valued at $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the third quarter valued at $28,000. Virtus Advisers LLC bought a new stake in shares of Hims & Hers Health in the 2nd quarter valued at about $26,000. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the 2nd quarter worth approximately $29,000. Finally, Bessemer Group Inc. boosted its stake in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Trading Down 0.5%

The stock has a market capitalization of $3.51 billion, a P/E ratio of 30.26, a P/E/G ratio of 2.90 and a beta of 2.43. The stock’s 50 day moving average price is $27.79 and its 200-day moving average price is $39.76. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.25% and a net margin of 5.47%.Hims & Hers Health’s revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.11 earnings per share. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has initiated a stock repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.